Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.

Cyrus Cooper, Ronald D Emkey, Robert H McDonald, Gillian Hawker, Gerolamo Bianchi, Katie Wilson, Ralph C Schimmer

Journal: The Journal of clinical endocrinology and metabolism 2003;88(10):4609-15

PMID: 14557430

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Adherence to oral daily bisphosphonate regimens in postmenopausal osteoporosis is currently suboptimal. Less frequent dosing regimens are likely to improve patient adherence and thus, potentially, patient outcomes. A multicenter, randomized, double-blind, noninferiority study was conducted in 235 women (53-80 yr old; time since menopause >/==" BORDER="0"> 3 yr) with postmenopausal osteoporosis [lumbar spine (L1-L4) bone mineral density (BMD) T-score

Address: Southampton General Hospital, Medical Research Council Environmental Epidemiology Unit, Southampton, SO16 6YD United Kingdom. [email protected]

DOI: 10.1210/jc.2003-022029

Link outs

Free resources

Medical:

https://medlineplus.gov/bonedensity.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Administration, Oral, Aged, Biomarkers, Bone Density, Diphosphonates, Double-Blind Method, Female, Humans, Ibandronic Acid, Lumbar Vertebrae, Middle Aged, Osteoporosis, Postmenopausal, Treatment Outcome